At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 49 enrolled
Drug / intervention
varenicline +1 moredrug
Likely dose
varenicline 1mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Smoking Cessation Study for Newly Diagnosed Lung Cancer Patients
In Brief
A Phase 2 clinical trial evaluating Smoking cessation counseling and varenicline for Lung Cancer. Completed, enrolled 49 participants across 1 site.
Detailed Summary
The primary aim of the proposed study is to develop and assess the feasibility of delivering a smoking cessation intervention to patients undergoing lung surgery that begins before surgery and continues up to 3 months post-discharge. The secondary aim is to assess smoking cessation rates 3 months following surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 2007
Enrollment StartJan 2008
Primary CompletionApr 2012
TodayJul 2026
First PostedDec 24, 2007
Enrollment StartJan 1, 2008
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 18.5 years ago
Interventions
Smoking cessation counselingbehavioral
Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
vareniclinedrug
varenicline (1mg bid, with initial titration up over week 1) for 12 weeks